TEVA-CODEINE TABLET

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

CODEINE PHOSPHATE

Dostupné z:

TEVA CANADA LIMITED

ATC kód:

R05DA04

INN (Medzinárodný Name):

CODEINE

Dávkovanie:

30MG

Forma lieku:

TABLET

Zloženie:

CODEINE PHOSPHATE 30MG

Spôsob podávania:

ORAL

Počet v balení:

100/500

Typ predpisu:

Narcotic (CDSA I)

Terapeutické oblasti:

OPIATE AGONISTS

Prehľad produktov:

Active ingredient group (AIG) number: 0104398004; AHFS:

Stav Autorizácia:

APPROVED

Dátum Autorizácia:

2002-02-06

Súhrn charakteristických

1
PRESCRIBING
INFORMATION
N
TEVA-CODEINE
CODEINE PHOSPHATE TABLETS USP
15 MG AND 30 MG
TABLETS
OPIOID
ANALGESIC/ANTITUSSIVE
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada
M1B 2K9
www.tevacanada.com
Control #: 225991
Date of Revision:
November 5, 2019
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS ....................... ERROR! BOOKMARK
NOT DEFINED.
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
REFERENCES
..................................................................
ERROR! BOOKMARK NOT DEFINED.
PATIENT MEDICATION INFORMATION
............